Qiong He

Qiong He

Auto-generated profile, based on publicly available information

Qiong He

Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, 030001 Shanxi Province, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2021 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
QHQiong He
Qiong He
JBJiaqi Bo
Jiaqi Bo
RSRuihua Shen
Ruihua Shen
YLYan Li
Yan Li
YZyi zhang
yi zhang
YLYunfeng Liu
Yunfeng Liu
The pathogenesis of type 2 diabetes mellitus (T2DM) is very complicated. The currently well-accepted etiology is the Ominous Octet theory proposed by Professor Defronzo. Since presently used drugs for T2DM have limitations and harmful side effects, studies regarding alternative treatments are being conducted. Analyzing the pharmacological mechanism of biomolecules in view of pathogenesis is an effective way to assess new drugs. Sphingosine 1 phosphate (S1P), an endogenous lipid substance in the human body, has attracted increasing attention in the T2DM research field. This article reviews recent study updates of S1P, summarizing its effects on T2DM with respect to pathogenesis, promoting β cell proliferation and inhibiting apoptosis, reducing insulin resistance, protecting the liver and pancreas from lipotoxic damage, improving intestinal incretin effects, lowering basal glucagon levels, etc. With increasing research, S1P may help treat and prevent T2DM in the future.

25 February 2021 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
QHQiong He
Qiong He
GDGaofeng Ding
Gaofeng Ding
MZMengyuan Zhang
Mengyuan Zhang
PNPeng Nie
Peng Nie
JYJing Yang
Jing Yang
YLYunfeng Liu
Yunfeng Liu
Objectives. This study was designed to explore the intellectual landscape of research into the application of sphingosine 1 phosphate (S1P) in age-related diseases and to identify thematic development trends and research frontiers in this area. Methods. Scientometric research was conducted by analyzing bibliographic records retrieved from the Web of Science (WOS) Sci-Expanded Database dated between 1900 and 2020. Countries, institutions, authors, keyword occurrence analysis, and cooperation network analysis were performed using the CiteSpace and VOSviewer software. Results. A total of 348 valid records were included in the final dataset, and the number of publications and the frequency of citations have grown rapidly over the last ten years. The USA ( ), China ( ), and Germany ( ) were the three largest contributors to the global publications on S1P and aging, while the Medical University of South Carolina ( ), University of California, San Francisco ( ), and University of Toronto ( ) were the leading institutions in this field. Analysis showed that early studies primarily focused on the mechanism of S1P intervention in AD. While S1P and its relevant metabolites have remained a long-term active area of research, recent studies have focused more on interventions aimed at improving retinal degeneration, cardiomyopathy, multiple sclerosis, and diabetes, among others. Conclusions. It is worth mentioning that this manuscript is the first to describe any bibliometric analysis of S1P and its application in age-related interventions. This study includes a discussion of the (1) historical overview of the topic; (2) main contributors: journals, countries, institutes, funding agencies, and authors; (3) collaboration between institutes and authors; (4) research hot spots and zones; and 5) research trends and frontiers. This will enable scholars to understand the current status of S1P research in age-related diseases.